Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05458453
Other study ID # Esketamine and thoracoscopic
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date July 7, 2022
Est. completion date February 28, 2023

Study information

Verified date August 2022
Source The Second Affiliated Hospital of Chongqing Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Thoracic surgery can produce severe postoperative acute pain, which can easily lead to cough weakness, atelectasis, respiratory restriction, pneumonia, hypoxemia, secretion retention, respiratory failure and other adverse events. Esketamine can reduce the demand of analgesic opioids, reduce the respiratory depression caused by opioids, improve ventilation, significantly reduce postoperative pain and prolong the analgesic time after thoracic surgery. Therefore, the application of esketamine in postoperative analgesia of patients undergoing thoracoscopic surgery may help to improve the respiratory function of clinical patients and further improve the postoperative analgesia effect, so as to achieve the purpose of accelerating the surgical rehabilitation of patients undergoing thoracoscopic surgery. Esketamine is rarely used in perioperative period in China, and the development of its safe and reasonable application methods and potential role in perioperative anesthesia needs further research and verification. Generally speaking, at present, there is still a lack of evaluation of ketamine in improving respiratory function, pain, anxiety and depression after thoracoscopic surgery, and there is no direct clinical evidence. At present, sufentanil is the most commonly used drug for postoperative analgesia in patients undergoing clinical surgery. As a strong opioid, although sufentanil can provide good analgesic effect, the respiratory depression caused by sufentanil is not conducive to the recovery of postoperative lung function in patients undergoing thoracic surgery. The action sites of esketamine include N- methyl-aspartic acid (NMDA) receptor, opioid receptor, monoamine receptor, M cholinergic receptor, sodium channel, calcium channel, etc., which can relieve respiratory depression caused by opioids, stimulate respiration, relax airway smooth muscle, prevent hyperalgesia caused by opioids, reduce the dosage of postoperative analgesics and prolong the duration of postoperative analgesia. Therefore, esketamine is likely to improve postoperative respiratory function of patients after thoracoscopic surgery and play a good role. To sum up, this study is intended to include patients undergoing elective thoracoscopic surgery. Through a prospective randomized controlled double-blind clinical trial, different analgesic drugs of intravenous patient-controlled analgesia and simple conventional opioid analgesic sufentanil are used as the control. Combined with the investigation of preoperative and postoperative tidal volume, oxygenation index, postoperative pain and postoperative recovery outcome, the effects of esketamine on postoperative respiratory function, postoperative pain and overall rehabilitation of these patients are compared, so as to provide direct clinical evidence for improving postoperative lung function of patients undergoing elective thoracoscopic surgery, and at the same time, provide a choice for thoracoscopic surgery. To explore the effect of esketamine on improving postoperative respiratory function, pain, depression and anxiety and overall rehabilitation of patients undergoing thoracoscopic surgery. Compound esketamine is used for postoperative analgesia, thus providing direct clinical evidence for improving postoperative pulmonary function of patients undergoing elective thoracoscopic surgery, and providing reference for improving postoperative pain, anxiety and depression of patients undergoing elective thoracoscopic surgery.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date February 28, 2023
Est. primary completion date February 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Patients undergoing thoracoscopic surgery are required to use PCIA for analgesia; 2. ASA grade I-III; 3. The patient's age is 18-75 years old; 4?18.5 < BMI < 28; 5. Obtain the informed consent of patients and their families; Exclusion Criteria: 1. Patients with previous history of thoracic surgery or combined history of thoracic trauma; 2. Patients with severe hypertension and poor control; 3. Patients with hyperthyroidism and poor control; 4. Patients at risk of increased intracranial pressure; 5. Patients with mental illness; 6. Patients who are allergic to any drug in the test; 7. Patients who take anti-inflammatory drugs, opioids or related diseases for a long time; 8. Pregnant or lactating patients;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Esketamine
Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ esketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).

Locations

Country Name City State
China Department of Anesthesiology, The Second Affiliated Hospital, Chongqing Medical University Chongqing Chongqing
China The Second Affiliated Hospital, Chongqing Medical University Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
The Second Affiliated Hospital of Chongqing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Depression scale 0 PHQ-9, The higher the score, the more depressed. Before anesthesia induction
Other Depression scale 2 PHQ-9,The higher the score, the more depressed. Day 1(the first morning after using PCIA)
Other Depression scale 4 PHQ-9,The higher the score, the more depressed. day 2 ( second morning after using PCIA)
Other anxiety score 0 GAD-7,The higher the score, the more anxious. Before anesthesia induction
Other anxiety score 2 GAD-7,The higher the score, the more anxious. Day1(the first morning after using PCIA)
Other anxiety score 4 GAD-7,The higher the score, the more anxious. day 2 ( second morning after using PCIA)
Other sleep quality during the first two days after surgery assessed by Richards-Campbell sleep score, which higher socre represents better sleep quality from end of the surgery to the second day after surgery
Primary Minute ventilation volume 0 Minute ventilation volume before anesthesia induction Before anesthesia induction
Primary Minute ventilation volume 1 Minute ventilation volume after extubation Within 5 minutes after extubation
Primary Minute ventilation volume 2 Minute ventilation volume on the first morning postoperative day 1 (POD1) morning
Primary Minute ventilation volume 3 Minute ventilation volume on the first afternoon postoperative day 1 (POD1) afternoon
Primary Minute ventilation volume 4 Minute ventilation volume on the next morning postoperative day 2 (POD2) morning
Primary Minute ventilation volume 5 Minute ventilation volume on the next afternoon postoperative day 2 (POD2) afternoon
Primary Tidal volume 0 Tidal volume before anesthesia induction Before anesthesia induction
Primary Tidal volume 1 Tidal volume after extubation Within 5 minutes after extubation
Primary Tidal volume 2 Tidal volume on the first morning after surgery Day1 (The first morning after surgery)
Primary Tidal volume 3 Tidal volume on the first afternoon after surgery Day1(The afternoon of the first day after surgery)
Primary Tidal volume 4 Tidal volume on the next morning after surgery day 2 ( second morning after surgery)
Primary Tidal volume 5 Tidal volume on the next afternoon after surgery day 2 ( second afternoon after surgery)
Primary Respiratory rate 0 Respiratory rate before anesthesia induction Before anesthesia induction
Primary Respiratory rate 1 Respiratory rate after extubation Within 5 minutes after extubation
Primary Respiratory rate 2 Respiratory rate on the first morning after surgery Day1 (The first morning after surgery)
Primary Respiratory rate 3 Respiratory rate on the first afternoon after surgery Day1 (The afternoon of the first day after surgery)
Primary Respiratory rate 4 Respiratory rate on the next morning after surgery day 2 ( second morning after using surgery)
Primary Respiratory rate 5 Respiratory rate on the next afternoon after surgery day 2 ( second afternoon after surgery)
Secondary Vas score 1 The higher the score, the more painful it is. Within 5 minutes after extubation
Secondary Vas score 2 The higher the score, the more painful it is. postoperative day 1 (POD1) morning
Secondary Vas score 3 The higher the score, the more painful it is. postoperative day 1 (POD1) afternoon
Secondary Vas score 4 The higher the score, the more painful it is. postoperative day 2 (POD2) morning
Secondary Vas score 5 The higher the score, the more painful it is. postoperative day 2 (POD2) afternoon
Secondary Oxygenation index 0 Oxygenation index (calculated as PaO2/FiO2) before anesthesia induction Before anesthesia induction
Secondary Oxygenation index 1 Oxygenation index (calculated as PaO2/FiO2) after extubation Within 5 minutes after extubation
Secondary Oxygenation index 3 Oxygenation index (calculated as PaO2/FiO2) on the first morning postoperative Day 1
Secondary Incidence of postoperative pulmonary complications during hospitalization postoperative pulmonary complications during hospitalization was assessed using the Melbourne Group Scale, whcih reached four or more of the 8 criteria would be diagnosed with postoperative pulmonary complications. From end of the surgery to hospital discharge with about mean of 7 days after surgery
Secondary incidence of hypoxemia during the first and second day after surgery hypoxemia is defined as SpO2<92% during the first and second day after surgery from end of the surgery to the second day after surgery
See also
  Status Clinical Trial Phase
Completed NCT05506787 - The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease Phase 4
Not yet recruiting NCT06062550 - Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery Phase 4
Recruiting NCT06003218 - Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation N/A
Recruiting NCT04664530 - The Study on the Esketamine in the Treatment of Postherpetic Neuralgia Phase 4
Not yet recruiting NCT06117917 - Esketamine Combined With Pregabalin on CPSP in Spinal Patients. Phase 2/Phase 3
Recruiting NCT05950646 - Mini-dose Dexmedetomidine-Esketamine Infusion and Perioperative Sleep Quality Phase 4
Recruiting NCT05718024 - Night-time Dexmedetomidine-esketamine Infusion and Sleep Quality With Mechanical Ventilation Phase 4
Recruiting NCT05732064 - Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality Phase 4
Not yet recruiting NCT06399185 - Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort Phase 4
Not yet recruiting NCT06389344 - Effect of Esketamine on Conscious State in Patients With pDoC N/A
Recruiting NCT04860661 - Esketamine on Postpartum Depression in Cesarean Section Women N/A
Completed NCT06398834 - Esketamine and Butorphanol for Post-Lobectomy Pain Phase 4
Recruiting NCT04843982 - Immunoinflammatory Regulation of Esketamine in Septic Patients Phase 4
Not yet recruiting NCT05943028 - Effect of Subanesthetic Dose Esketamine on Propofol-refentanil Closed-loop Targeted Controlled Infusion Early Phase 1
Active, not recruiting NCT05718544 - Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia and Long-term Outcomes Phase 4
Not yet recruiting NCT06087510 - Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes Phase 4
Recruiting NCT06051227 - Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial Phase 3
Recruiting NCT04425473 - Esketamine and Perioperative Depressive Symptoms Phase 2/Phase 3
Completed NCT05096468 - Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms. Phase 2/Phase 3
Not yet recruiting NCT04777110 - The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy Early Phase 1